Literature DB >> 11580994

Haemodynamic changes following treatment of subclinical and overt hyperthyroidism.

J Faber1, N Wiinberg, S Schifter, J Mehlsen.   

Abstract

OBJECTIVE: Hyperthyroidism has profound effects on the cardiovascular system, including reduced systemic vascular resistance (SVR) due to relaxation of vascular smooth muscle cells, enhanced heart rate (HR) and cardiac output (CO) due to an increase in cardiac diastolic relaxation, contractility and heart rate. Subclinical hyperthyroidism is characterised by reduced serum TSH levels despite free thyroxine (T4) and tri-iodothyronine (T3) estimates within the reference range, in subjects with no obvious symptoms of hyperthyroidism. We measured haemodynamic changes (using impedance cardiography) in subjects with endogenous subclinical hyperthyroidism in order to elucidate whether these patients had signs of excess thyroid hormone at the tissue level.
DESIGN: The patients were otherwise healthy women with a multinodular goitre (n=6; age 47-81 years; serum TSH 0.006-0.090 mU/l and normal free T4 and T3 estimates), studied before and after normalisation of TSH (0.280-1.120 mU/l) by means of radioiodine treatment, and they were compared with 9 overt hyperthyroid patients (2 with multinodular goitre and 7 with Graves' disease) in the untreated state and after euthyroidism had been obtained.
RESULTS: Treatment of the subclinical hyperthyroid women resulted in 11% reduction in HR (P<0.02), 19% reduction in CO from (means+/-s.d.) 6.93+/-2.15 l/min to 5.58+/-1.94 l/min (P<0.05), and 30% increase in SVR (P<0.02). Similar but more pronounced changes were seen in the hyperthyroid group: 17% reduction in HR, 25% reduction in CO and 46% increase in SVR (all at least P<0.05). Taking all 15 patients together, thyroid function (as measured by free T3 index (FT3I) or TSH) correlated significantly to the haemodynamic parameters as follows: the higher the thyroid function the lower the mean arterial pressure and SVR, and the higher the CO and central aortic compliance (stroke volume/pulse pressure) (P<0.05). Plasma norepinephrine increased significantly after treatment of the overt hyperthyroid patients, whereas epinephrine did not change, and no changes were seen among subclinical hyperthyroid patients.
CONCLUSION: Treatment of endogenous subclinical hyperthyroidism resulted in significant changes in several haemodynamic parameters regarding the heart and the vascular system, compatible with some degree of excess tissue exposure to thyroid hormones in the untreated state. Our data favour more aggressive treatment of these patients, and endogenous subclinical hyperthyroidism might be regarded as a mild form of hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580994     DOI: 10.1530/eje.0.1450391

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

1.  Subclinical hyperthyroidism increases risk of coronary heart disease events in type 2 diabetes mellitus.

Authors:  Jin Geng; Weiping Lu; Tingting Hu; Sha Tao; Hongman Zhang; Juan Chen; Yanlong Bu; Shuren Ma; Bingjian Wang
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

2.  High serum thyrotropin levels are associated with current but not with incident hypertension.

Authors:  Till Ittermann; Daniel Tiller; Christa Meisinger; Carsten Agger; Matthias Nauck; Rainer Rettig; Albert Hofman; Torben Jørgensen; Allan Linneberg; Jacqueline C M Witteman; Oscar H Franco; Karin H Greiser; Karl Werdan; Angela Döring; Alexander Kluttig; Bruno H C Stricker; Henry Völzke
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

3.  Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

4.  Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Circulation       Date:  2019-05-13       Impact factor: 29.690

Review 5.  Subclinical hyperthyroidism: to treat or not to treat?

Authors:  E H Hoogendoorn; M den Heijer; A P J van Dijk; A R Hermus
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

6.  Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism.

Authors:  S Buscemi; S Verga; S Cottone; G Andronico; L D'Orio; V Mannino; D Panzavecchia; F Vitale; G Cerasola
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

7.  Hemodynamic changes in neonates born to mothers with Graves' disease.

Authors:  Takamichi Ishikawa; Hiroki Uchiyama; Satoru Iwashima; Toru Baba; Akira Ohishi; Shigeo Iijima; Hiroaki Itoh
Journal:  Endocrine       Date:  2020-08-12       Impact factor: 3.633

Review 8.  Hyperthyroidism.

Authors:  Mala Sharma; Wilbert S Aronow; Laxesh Patel; Kaushang Gandhi; Harit Desai
Journal:  Med Sci Monit       Date:  2011-04

9.  The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study.

Authors:  Christian Selmer; Jonas Bjerring Olesen; Morten Lock Hansen; Jesper Lindhardsen; Anne-Marie Schjerning Olsen; Jesper Clausager Madsen; Jens Faber; Peter Riis Hansen; Ole Dyg Pedersen; Christian Torp-Pedersen; Gunnar Hilmar Gislason
Journal:  BMJ       Date:  2012-11-27

10.  New-onset atrial fibrillation is a predictor of subsequent hyperthyroidism: a nationwide cohort study.

Authors:  Christian Selmer; Morten Lock Hansen; Jonas Bjerring Olesen; Charlotte Mérie; Jesper Lindhardsen; Anne-Marie Schjerning Olsen; Jesper Clausager Madsen; Ulla Schmidt; Jens Faber; Peter Riis Hansen; Ole Dyg Pedersen; Christian Torp-Pedersen; Gunnar Hilmar Gislason
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.